Healthcare & Life Sciences Non-Executive Recruitment

Healthcare & Life Sciences NED Recruitment

NED Capital places non-executive directors for NHS trusts, NHS foundation trusts, integrated care boards, private hospital groups, independent healthcare providers, pharmaceutical companies, medical device businesses, biotech companies, digital health platforms and life sciences organisations across the UK. Healthcare and life sciences governance encompasses the most diverse and most regulated set of governance environments in the UK NED market — NHS governance operates under a specific statutory and regulatory framework that differs entirely from commercial company governance, life sciences businesses face MHRA and FDA regulatory approval processes that are central to their commercial viability, and biotech governance requires oversight of clinical development programmes that non-specialists cannot assess without direct sector experience. Adrian Lawrence FCA, founder of NED Capital and Fellow of the ICAEW, leads every healthcare and life sciences NED search personally.

Call 0203 137 2496 or email recruitment@nedcapital.co.uk to discuss a healthcare or life sciences NED appointment.

NHS Trust and Foundation Trust Governance

NHS trusts and NHS foundation trusts are governed within a specific statutory and regulatory framework that differs materially from commercial company governance. NEDs on NHS boards — formally called Non-Executive Directors in NHS trusts and Governors in NHS foundation trusts — operate under the NHS Foundation Trust Code of Governance, NHS England’s oversight framework and the Care Quality Commission’s Well-Led regulatory domain.

NHS Foundation Trust Code of Governance. The NHS Foundation Trust Code of Governance — based on the FRC Code but adapted for the NHS context — sets out the governance requirements for foundation trust boards. It requires appropriate board composition (balance of executive and non-executive directors), annual board effectiveness review, specific committee requirements (audit, remuneration, quality governance) and transparency in governance reporting. Foundation trusts with a Council of Governors have the additional governance complexity of managing the relationship between the board of directors and the council — a unique governance structure that has no commercial company equivalent.

The Well-Led framework. The Care Quality Commission’s Well-Led domain — one of the five domains that CQC uses to assess healthcare providers — evaluates the governance, leadership and culture of healthcare organisations. CQC inspectors assess whether the board and leadership team have the right skills, experience and values; whether there are effective processes for identifying and managing risk; and whether the organisation’s culture promotes openness, candour and continuous improvement. A CQC inspection that identifies governance weaknesses in the Well-Led domain can result in a “Requires Improvement” or “Inadequate” rating that triggers NHS England regulatory intervention. NEDs on NHS trust boards are directly accountable for the governance quality that the Well-Led framework assesses.

NHS oversight framework. NHS England’s NHS Oversight Framework provides a tiered approach to NHS trust oversight — ranging from standard oversight through to System Oversight Framework recovery support and NHS England intensive support for trusts in serious financial or governance difficulty. Trusts in “segment 4” (the most intensive oversight category) face direct NHS England intervention in their governance and management. NEDs joining trusts under intensive oversight need specific awareness of the oversight process and what it requires of the board.

NHS financial governance. NHS trusts and foundation trusts operate under the NHS Financial Reporting Manual (FReM) — a specific financial reporting framework that differs from both IFRS and UK GAAP. Financial NEDs on NHS boards need awareness of the FReM framework, NHS capital allocation processes, the Control Total framework for managing NHS deficits and the specific financial governance obligations of NHS statutory bodies. The ongoing financial pressures across the NHS — with a significant proportion of trusts in deficit — make financial governance and financial recovery planning a primary board accountability across the sector.

Patient Safety Governance — The Primary Clinical Accountability

Patient safety is the most important and most distinctive governance responsibility on any healthcare board — NHS or private. The consequences of patient safety governance failure are not financial penalties or reputational damage (though those follow) — they are harm to patients who have trusted the healthcare organisation with their clinical care. The board’s patient safety governance function must be treated with the seriousness that this primary obligation demands.

Duty of Candour. The statutory Duty of Candour — introduced for NHS and private healthcare providers by the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 — requires healthcare providers to be open and transparent with service users when things go wrong. When a patient safety incident results in moderate harm or above, the provider must notify the patient (or their family), provide a verbal and written apology, investigate what happened and explain what will be done to prevent recurrence. The board’s governance of the Duty of Candour — ensuring that the organisation is meeting its statutory obligations, that staff are supported to be candid about errors and that learning from incidents is embedded — is a primary governance accountability.

PSIRF — Patient Safety Incident Response Framework. The Patient Safety Incident Response Framework (PSIRF), introduced in 2023 to replace the Never Events framework, provides a new approach to learning from patient safety incidents. Rather than focusing on a specific list of “never events” (incidents that should never occur), PSIRF requires organisations to develop a patient safety incident response plan that reflects the organisation’s specific risk profile and directs investigation capacity to those incidents most likely to generate learning. The board’s governance of PSIRF implementation — approving the patient safety incident response plan, monitoring the quality of safety investigations and ensuring learning is acted on — is a specific and current governance obligation for NHS and private healthcare boards.

Private Healthcare and Independent Providers

Private healthcare providers — private hospital groups (Spire Healthcare, Nuffield Health, Circle Health Group, Ramsay Health Care UK), independent clinics, private GP services, dentistry chains and primary care networks — are regulated by the CQC as regulated activities providers. CQC registration and inspection applies to private providers in the same way as to NHS providers, and the Well-Led domain governs their board governance quality as it does NHS trusts.

Private healthcare governance has specific commercial characteristics that distinguish it from NHS governance. Private providers compete for patients in a market where quality, reputation and consultant relationships are primary competitive factors. The board’s governance of the quality and safety record — and its relationship to the commercial performance and market positioning of the business — requires NEDs who can bridge clinical governance and commercial governance in a way that is specific to the private healthcare market.

Private equity investment in private healthcare has been significant — the major private hospital groups, domiciliary care businesses and specialist clinical services have attracted substantial PE and infrastructure investment. PE-backed private healthcare NEDs need to govern the commercial and operational performance alongside the clinical governance obligations, understanding that patient safety and clinical quality are non-negotiable constraints on the value creation programme rather than governance areas to be traded off against commercial objectives.

Life Sciences — MHRA, MDR and Regulatory Governance

The governance of life sciences companies — pharmaceutical manufacturers, medical device businesses, diagnostics companies and clinical research organisations (CROs) — is shaped by the specific regulatory frameworks governing the development, approval and commercialisation of medicines and medical devices.

MHRA regulatory governance. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines and medical devices in the UK. Post-Brexit, the UK has established its own medicines licensing pathway — the MHRA’s UK approval process is separate from the EMA’s EU approval process, though international recognition agreements seek to reduce duplicate review work. The board’s governance of regulatory strategy — when to submit for MHRA approval, how to manage the EMA parallel process for EU market access, and how to navigate the FDA approval process for US market ambitions — is a primary strategic governance function for life sciences businesses.

Medical Device Regulation (MDR). The governance of medical device development and commercialisation involves compliance with the MHRA’s UK MDR framework and, where EU market access is sought, the EU MDR 2017/745. The board’s oversight of MDR compliance — CE/UKCA marking, notified body engagement, post-market surveillance and vigilance reporting — is a specific regulatory governance accountability for medical device companies.

Good Clinical Practice (GCP) and trial governance. Clinical trials — the primary mechanism through which pharmaceutical and biotech companies develop evidence for regulatory approval — are governed by Good Clinical Practice (GCP) standards, which are legally required under UK clinical trials legislation. The board’s governance of clinical trial management — the oversight of principal investigators, trial site management, data integrity and safety reporting — is a specific governance function that requires NEDs with direct experience of regulated clinical research.

Biotech and Drug Development Governance

Biotech companies — early-stage businesses developing novel therapeutics, gene therapies, cell therapies, diagnostic platforms or medical technologies — present specific governance challenges that reflect the high-risk, long-duration nature of drug development and the VC or growth equity funding environment in which most biotech companies operate.

Clinical programme governance. The board’s oversight of a clinical development programme — the sequence of Phase 1, 2 and 3 trials required to generate safety and efficacy evidence for regulatory approval — requires NEDs who can assess whether the clinical strategy is appropriate, whether trial design is robust and whether the programme is progressing at the expected pace and cost. Clinical programme governance is a specific area where scientific advisory board input to the main board, and main board NEDs with clinical development experience, are essential.

IP and patent governance. The commercial viability of a biotech company depends critically on its patent estate — the patents protecting its lead compounds, its delivery mechanisms and its manufacturing processes. Patent term management (maximising the commercial period of patent protection), freedom to operate assessments (ensuring the company is not infringing third-party IP), and the governance of patent prosecution and litigation are primary governance functions for biotech boards. The board must understand that patent expiry is a known and manageable governance event — pipeline governance should ensure that successor products are in development before primary patents expire.

Financing and burn rate governance. Biotech companies are typically pre-revenue or early-revenue businesses with high cash burn rates from R&D investment. The governance of cash runway — ensuring the company has adequate funding to reach the next value inflection point, managing the timing and structure of fundraising rounds and overseeing bridge financing when required — is a primary financial governance function. NEDs who have governed biotech companies through financing cycles understand the specific governance challenges of managing a board that must simultaneously drive clinical progress, manage investor expectations and preserve sufficient financial runway to execute the clinical plan.

Healthcare and Life Sciences NED Fee Benchmarks

Healthcare governance NED fees vary substantially by organisation type. NHS trust and foundation trust NEDs: £7,000–£15,000 per annum (set by DHSC guidance); NHS trust chairs: £30,000–£65,000. Private healthcare companies: listed entities £40,000–£85,000; PE-backed private healthcare £30,000–£60,000 with equity. Life sciences listed companies: £45,000–£85,000. Biotech and growth-stage life sciences: £20,000–£50,000 with equity component (options are particularly important given the potential for significant value creation at clinical milestones). Chair roles at 1.5–2x the standard NED fee.